Clene (CLNN) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free CLNN Stock Alerts $0.39 +0.00 (+0.78%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 8:18 AM | finance.yahoo.comClene to Present at Upcoming May ConferencesMay 14 at 8:00 AM | globenewswire.comClene to Present at Upcoming May ConferencesMay 13 at 2:40 AM | americanbankingnews.comQ2 2024 EPS Estimates for Clene Inc. (NASDAQ:CLNN) Decreased by Roth CapitalMay 13 at 2:40 AM | americanbankingnews.comResearch Analysts Offer Predictions for Clene Inc.'s Q2 2024 Earnings (NASDAQ:CLNN)May 12, 2024 | americanbankingnews.comClene Inc. to Post FY2028 Earnings of $0.91 Per Share, Roth Capital Forecasts (NASDAQ:CLNN)May 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)May 10, 2024 | marketbeat.comFY2028 EPS Estimates for Clene Inc. (NASDAQ:CLNN) Boosted by AnalystClene Inc. (NASDAQ:CLNN - Free Report) - Equities research analysts at Roth Capital raised their FY2028 earnings per share estimates for Clene in a report released on Wednesday, May 8th. Roth Capital analyst J. Aschoff now anticipates that the company will earn $0.91 per share for the year, up frMay 10, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation HighlightsMay 9, 2024 | finance.yahoo.comClene First Quarter 2024 Earnings: Misses ExpectationsMay 8, 2024 | finanznachrichten.deClene Inc.: Clene Reports First Quarter 2024 Financial Results and Recent Operating HighlightsMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Clene (CLNN)May 8, 2024 | investorplace.comCLNN Stock Earnings: Clene Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comClene Reports First Quarter 2024 Financial Results and Recent Operating HighlightsMay 1, 2024 | finance.yahoo.comIBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob EtheringtonApril 23, 2024 | finance.yahoo.comBullish Clene Insiders Loaded Up On US$9.58m Of StockApril 17, 2024 | benzinga.comThe Analyst Verdict: Clene In The Eyes Of 5 ExpertsApril 16, 2024 | msn.comClene stock rallies 52% post-market on MS drug dataApril 16, 2024 | globenewswire.comEvidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual MeetingMarch 28, 2024 | marketbeat.comClene Inc. (NASDAQ:CLNN) Short Interest Down 38.5% in MarchClene Inc. (NASDAQ:CLNN - Get Free Report) was the target of a large drop in short interest in March. As of March 15th, there was short interest totalling 262,500 shares, a drop of 38.5% from the February 29th total of 427,100 shares. Based on an average daily volume of 1,090,000 shares, the short-interest ratio is currently 0.2 days.March 27, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MSMarch 26, 2024 | investorplace.com3 Penny Stocks That Could Be Multibaggers in the Making: March EditionMarch 20, 2024 | marketbeat.comClene's (CLNN) "Buy" Rating Reaffirmed at BenchmarkBenchmark restated a "buy" rating and issued a $5.00 target price on shares of Clene in a report on Wednesday.March 19, 2024 | finance.yahoo.comIBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob EtheringtonMarch 17, 2024 | morningstar.comClene Inc Ordinary SharesMarch 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clene Amid Positive ALS Drug Data and Market DynamicsMarch 15, 2024 | marketbeat.comHC Wainwright Weighs in on Clene Inc.'s FY2028 Earnings (NASDAQ:CLNN)Clene Inc. (NASDAQ:CLNN - Free Report) - Equities research analysts at HC Wainwright lifted their FY2028 earnings estimates for shares of Clene in a report released on Wednesday, March 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $0.53March 15, 2024 | globenewswire.comClene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®March 14, 2024 | marketbeat.comClene Inc. (NASDAQ:CLNN) Short Interest UpdateClene Inc. (NASDAQ:CLNN - Get Free Report) was the recipient of a significant growth in short interest in February. As of February 29th, there was short interest totalling 427,100 shares, a growth of 86.8% from the February 14th total of 228,700 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is currently 0.4 days.March 13, 2024 | finanznachrichten.deClene Inc.: Clene Reports Full Year 2023 Financial Results and Recent Operating HighlightsMarch 13, 2024 | markets.businessinsider.comBreaking Down Clene: 4 Analysts Share Their ViewsMarch 13, 2024 | benzinga.comClene: Q4 Earnings InsightsMarch 13, 2024 | globenewswire.comClene Reports Full Year 2023 Financial Results and Recent Operating HighlightsMarch 7, 2024 | finance.yahoo.comClene to Present at the 36th Annual ROTH ConferenceFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clene’s CNM-Au8 on Promising Long-Term Clinical OutcomesFebruary 29, 2024 | globenewswire.comClene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024February 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clene Amidst Strong Clinical Data and Financial StabilityFebruary 22, 2024 | markets.businessinsider.comClene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use ProgramsFebruary 17, 2024 | finance.yahoo.comCLNN Mar 2024 1.000 putFebruary 17, 2024 | finance.yahoo.comCLNN Mar 2024 3.000 callFebruary 8, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive InterviewFebruary 6, 2024 | finance.yahoo.comIbogaine By David Dardashti Offers Free Online Support for Post-Treatment CareFebruary 6, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Reports Statistically Significant Long-Term Improvements for VISIONARY-MS ParticipantsFebruary 6, 2024 | marketbeat.comClene Inc. (NASDAQ:CLNN) Shares Sold by Vivo Capital LLCVivo Capital LLC reduced its stake in Clene Inc. (NASDAQ:CLNN - Free Report) by 41.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,645,338 shares of the company's stock after sellJanuary 24, 2024 | finance.yahoo.comClene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS TreatmentJanuary 23, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS TreatmentJanuary 11, 2024 | proactiveinvestors.comClene Inc. announces positive results from CNM-Au8 results from MS trialJanuary 10, 2024 | finance.yahoo.comClene Announces Significant Positive Results from LTE VISIONARY-MS TrialJanuary 9, 2024 | markets.businessinsider.comBuy Rating Affirmed: Clene’s CNM-Au8 Shows Promising Efficacy in MS Treatment StudyJanuary 8, 2024 | markets.businessinsider.comClene Announces Improvement In Vision, Cognition With CNM-Au8 TreatmentDecember 22, 2023 | markets.businessinsider.comOptimistic Buy Rating for Clene’s Stock Backed by Promising ALS Survival and Biomarker Data Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman. Get the full story here. CLNN Media Mentions By Week CLNN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLNN News Sentiment▼0.480.55▲Average Medical News Sentiment CLNN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLNN Articles This Week▼202▲CLNN Articles Average Week Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OCUP News Today AADI News Today HCWB News Today GANX News Today RMTI News Today XLO News Today IMRX News Today BLRX News Today SNSE News Today ELDN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLNN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressWATCH: The Truth About InflationBirch GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
